(Q30679247)

13 October 2017

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE. (English)

1 reference

13 October 2017

0 references

0 references

William Jeffery Sandborn

3

object named as

W J Sandborn

1 reference

13 October 2017

Jean-Frédéric Colombel

2

object named as

J-F Colombel

1 reference

13 October 2017

R Panaccione

1

1 reference

13 October 2017

G D'Haens

4

1 reference

13 October 2017

Q Zhou

5

1 reference

13 October 2017

P F Pollack

6

1 reference

13 October 2017

R B Thakkar

7

1 reference

13 October 2017

A M Robinson

8

1 reference

13 October 2017

language of work or name

English

0 references

publication date

22 September 2013

1 reference

Alimentary Pharmacology & Therapeutics

13 October 2017

1 reference

13 October 2017

38

1 reference

13 October 2017

10

1 reference

13 October 2017

1236-1247

1 reference

Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease

13 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4670480

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4670480

Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4670480

Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4670480

Development of the Crohn's disease digestive damage score, the Lémann score

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4670480

Dosage adjustment during long-term adalimumab treatment for Crohnʼs disease: Clinical efficacy and pharmacoeconomics

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4670480

Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: a systematic review

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4670480

Adalimumab for the treatment of fistulas in patients with Crohn's disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4670480

The genetics and immunopathogenesis of inflammatory bowel disease

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4670480

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4670480

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4670480

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4670480

Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease--the mechanisms of action of infliximab

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4670480

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

20 June 2018

1 reference

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease

21 January 2018

1 reference

Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease

21 January 2018

1 reference

Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

21 January 2018

1 reference

Adalimumab induces deep remission in patients with Crohn's disease.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4670480

Environmental risk factors in Crohn's disease and ulcerative colitis: an update

25 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24134498

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/APT.12499

1 reference

13 October 2017

1 reference

13 October 2017

PubMed publication ID

24134498

1 reference